Continued Pre-Market Rally For NeuroBo Pharmaceuticals' (NRBO) Stock
Continued Pre-Market Rally For NeuroBo Pharmaceuticals' (NRBO) Stock
The Series A warrants will expire sixty days after the public release of a favorable Phase 1 multiple ascending dose (MAD) data readout for DA-1726, or twelve months after the stockholder approval. The Series B warrants will expire either six months after the Phase 1 Part 3 data readout for DA-1726 is publicly announced or five years after the stockholder approval.As the market begins today, shares of NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) seem to be continuing their prior session's gain, propelled by news of recent and successful stock transactions. The pre-market trading activity for NRBO shares showed a 12.91% increase in value, closing at $4.81.
隨着市場今天的開始，NeuroBo Pharmaceuticals，Inc.（納斯達克：NRBO）的股票在繼續前一交易日的漲勢，迎來了最近成功的股票交易的資訊推動。NRBO股票的盤前交易活動顯示股票價值增加了12.91％，收盤價爲$4.81。
Equity Deals And Issues
股權交易和問題
NeuroBo Pharmaceuticals (NRBO) has completed its previously announced private placement, in which 4,325,701 shares of common stock were sold for $3.93 a share. The business concurrently issued and sold 763,359 shares of ordinary stock at the same price through a registered direct offering.
NeuroBo Pharmaceuticals（NRBO）已完成之前宣佈的私募股份配售，以每股$3.93的價格出售了4,325,701股普通股。同時業務通過一項註冊直接發行以相同價格發行並出售了763,359股普通股。
NeuroBo also issued unregistered Series A and Series B warrants to acquire up to 5,089,060 and 7,633,591 shares of common stock, respectively, in addition to the equity transactions. The exercise price of each set of warrants is $3.93 per share, and they can be exercised only with stockholder permission.
除了股權交易，NeuroBo還發行了未註冊的A和B系列認股權，分別可以獲得不超過5,089,060股和7,633,591股的普通股。每組認股權的行使價格爲每股$3.93，只能在股東許可的情況下行使。
The Series A warrants will expire sixty days after the public release of a favorable Phase 1 multiple ascending dose (MAD) data readout for DA-1726, or twelve months after the stockholder approval. The Series B warrants will expire either six months after the Phase 1 Part 3 data readout for DA-1726 is publicly announced or five years after the stockholder approval.
A系列認股權將在DA-1726獲得有利的1期多劑量（MAD）數據披露後60天內到期，或在股東批准後12個月內到期。B系列認股權將在DA-1726的1期第3部分數據披露後6個月內到期，或在股東批准後5年內到期。
Promising Pre-Clinical Data For DA-1726
DA-1726有着良好的預臨床數據
Recently, NeuroBo disclosed pre-clinical data indicating that DA-1726 demonstrated superior results in weight loss, retention of lean body mass, and lipid-lowering effects compared to survodutide in pre-clinical models. This data was presented by Tae-Hyoung Kim, the lead research scientist at Dong-A ST Research Center, at the American Diabetes Association (ADA) 84th Scientific Sessions held from June 21-24 in Orlando, Florida.
最近，NeuroBo披露了預臨床數據，表明DA-1726在減輕體重，保留肌肉和降低脂質方面展現了比survodutide更好的效果。此數據由東亞製藥股份有限公司研究中心首席研究科學家金泰炯在美國糖尿病學會於6月21日至24日在佛羅里達州奧蘭多舉行的第84屆科學會議上展示。
The presented data highlights that DA-1726 distinguishes itself from other obesity drugs in the same class, likely due to its unique GLP-1 and glucagon receptor activity ratio. In obese mouse models, DA-1726 significantly reduced cholesterol levels and induced superior weight loss compared to survodutide, while also exhibiting better glucose-lowering effects. Notably, DA-1726 showed superior weight loss and preservation of lean body mass compared to survodutide.
展示的數據凸顯出DA-1726與同一類別中其他減肥藥物的不同之處，可能是由於其獨特的GLP-1和胰高血糖素受體活性比。在肥胖的小鼠模型中，DA-1726顯著降低了膽固醇水平，比survodutide表現出更好的減重效果，同時也表現出更好的降糖效果。值得注意的是，與survodutide相比，DA-1726顯示了更好的減重和保留瘦體組織的效果。